Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ramosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.83 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.83 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.83 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.83 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.83 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.83 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.83 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.83 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.83 |
| ▸ | HTR2B | P41595 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ramosetron SCHEMBL3175461 | 1.00 | HTR3A (0.83) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL30318895 | 1.00 | HTR3A (0.83) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL16701 | 0.99 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL13531398 | 0.99 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL9048395 | 0.99 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL2021739 | 0.99 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL29395241 | 0.99 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL9052272 | 0.93 | HTR3A (0.75) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL9048659 | 0.93 | HTR3A (0.75) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL8544326 | 0.92 | HTR3A (0.98) | HTR3AADRA2AADRA2BHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 754 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20250222003-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-07-10 | — | — | US | claimed |
| EP-3357945-B1 | ADHESIVE POLYMER AND MEDICAL ADHESIVE PATCH | TEIKOKU SEIYAKU KK (JP) | 2024-10-30 | — | — | EP | claimed |
| US-20240315956-A1 | METHOD OF PRODUCTION OF THE COMPOSITION OF CYCLOOXYGENASE-2 (COX-2) INHIBITORS | US Nano Food & Drug INC | 2024-09-26 | — | — | US | claimed |
| EP-4364742-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | Eisai R&D Management Co., Ltd. (JP) | 2024-05-08 | — | — | EP | claimed |
| CN-117813089-A | Process for producing cyclooxygenase-2 (COX-2) inhibitor composition | 美国纳米食品药品公司 | 2024-04-02 | — | — | CN | claimed |
| CN-117794544-A | Pharmaceutical composition for treating solid tumor | 卫材R&D管理有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117771191-A | Ramosetron hydrochloride injection freeze-dried powder and preparation method thereof | 杭州和康药业有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117229266-B | Method for synthesizing ramosetron racemate and salt thereof | 成都通德药业有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-117229266-A | Method for synthesizing ramosetron racemate and salt thereof | 成都通德药业有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-7358270-B2 | Treating agent for irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2008-04-15 | — | — | US | claimed |
| CN-100372533-C | Therapeutic formulation for mainly of diarrhea large intesitine irritation syndrome | ASTELLAS PHARMACY CO LTD (JP) | 2008-03-05 | — | — | CN | claimed |
| CN-101130080-A | Gelling agent for controlling and releasing 5-HT* acceptor antagon and method of preparing the same | UNIV SHANDONG (CN) | 2008-02-27 | — | — | CN | claimed |
| CN-1927398-A | Medicinal composition comprising active components of 5-HT 3 receptor antagonist and H2 receptor antagonist and use thereof | UNIV CHINA PHARMA (CN) | 2007-03-14 | — | — | CN | claimed |
| US-20070037866-A1 | 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt | ASTELLAS PHARMA INC. (JP) | 2007-02-15 | — | — | US | claimed |
| CN-1764453-A | Therapeutic formulation for mainly of diarrhea large intesitine irritation syndrome | ASTELLAS PHARMACY CO LTD (JP) | 2006-04-26 | — | — | CN | claimed |
| EP-1588707-A1 | STABLE SOLID MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-10-26 | — | — | EP | claimed |
| US-20050192329-A1 | Treating agent for irritable bowel syndrome | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-01 | — | — | US | claimed |
| EP-1559446-A1 | Treating agent for diarrhea-predominant irritable bowel syndrome | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-08-03 | — | — | EP | claimed |
| US-6440453-B1 | MIXTURE WITH TEA TREE OIL, ETHANOL AND WATER; SIDE EFFECT REDUCTION DURING CHEMOTHERAPY FOR CANCER AND/OR TUMORS | NOVOSIS PHARMA AG (DE) | 2002-08-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | SLC6A3, SLC6A4, HTR4 | HTR3A 4/4885HTR3E 8/4885HTR3B 12/4885 |
| US-20250222003-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | HTR3C, HTR3D, HTR3A | HTR3A 3/4885HTR3E 7/4885HTR3B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.